03:42 PM EST, 01/28/2025 (MT Newswires) -- Leap Therapeutics ( LPTX ) dropped 71% Tuesday after saying it will not move forward with phase 3 studies of sirexatamab for treatment of gastric cancer after initial data from part C of the ongoing study.

The trial evaluating sirexatamab in combination with tislelizumab and chemotherapy to treat gastroesophageal junction and gastric cancer did not generate a clear positive and on completion will not meet the primary progression-free survival goal, according to the company.

The company, however, will move forward with clinical trial to evaluate sirexatamab plus bevacizumab and chemotherapy to treat advanced colorectal cancer as a second-line treatment.

Price: 0.65, Change: -1.60, Percent Change: -71.02